Prothena Corporation plc (PRTA)
|52 Week Range||28.51-79.65|
|1y Target Est||-|
|DCF Unlevered||PRTA DCF ->|
|DCF Levered||PRTA LDCF ->|
|Debt / Equity||1.74%||Neutral|
Upgrades & Downgrades
Latest PRTA news
Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market
17 November 2023
Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.
Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike
3 November 2023
Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.
Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates
2 November 2023
Prothena (PRTA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.97 per share a year ago.
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
18 October 2023
Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?
17 October 2023
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro...
Prothena shares buoyed by sale rumors
16 October 2023
Shares of Prothena Corporation (NASDAQ:PRTA) added almost 25% on rumours the biotechnology firm is exploring a sale ahead of the release of key data from its highly anticipated Phase 1 Alzheimer's Dis...
Prothena prepares for potential sale - Bloomberg News
16 October 2023
Biotech firm Prothena Corp is preparing for a potential sale, Bloomberg News reported on Monday, citing people with knowledge of the matter.
Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise
21 September 2023
Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX012, is an amyloid clearing drug that is currently...
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
7 September 2023
Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.